Cullinan Therapeutics, Inc. CGEM
$13.59
▲ +5.55% 24H
About
Cullinan Therapeutics Inc. is an early-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company specializes in a range of innovative approaches including immuno-oncology and precision medicine. Its pipeline encompasses a variety of programs targeting defined mutations a…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees109
TickerCGEM
Statistics
Market Cap$835.1M
Revenue (TTM)—
Net Income-$219.9M
Net Margin—
EPS—
P/E9.03
P/S—
P/B2.02
EV/EBITDA-1.63
ROE-48.2%
Dividend Yield—
Price$13.59
Data: Twelve Data · Revenue = mcap / P/S